Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab)
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Genprex
Genprex is focused on developing life-changing gene therapies for cancer patients, leveraging its unique platform to deliver tumor suppressor genes directly to cancer cells. The company's core technology, the ONCOPREX® Nanoparticle Delivery System, is designed to overcome the limitations of viral vectors and enable systemic administration. Its lead program, Reqorsa®, which delivers the TUSC2 gene, is in multiple clinical trials for lung cancer, positioning the company at the forefront of non-viral gene therapy in oncology. Genprex's strategy involves advancing its pipeline through clinical development and seeking strategic partnerships to maximize the potential of its platform.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| TTFields | Novocure | Phase 3 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1/2 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |
| TG6050 | Transgene SA | Preclinical |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| Plinabulin | BeyondSpring | Phase 2/3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| ABD-3001 | Advanced Biodesign | Phase 1 |